Not FDA-approved1,3Evidence: Animal and lab onlyNot a peptideMetabolic and weight

5-Amino-1MQ1,2

Also called 5-Amino-1-methylquinolinium1

Not a peptide: a small molecule often looked up alongside peptides.

Key takeaway

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic compound, not a peptide. Researchers made it to block NNMT, an enzyme involved in how fat cells use energy.1,2 Its published evidence is laboratory and mouse research: in an 11-day study, obese mice given it lost weight and fat mass.2 No study in people and no FDA approval are reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,3,5

5-Amino-1MQ at a glance

Substance typeNot a peptide. FDA’s substance registry records 5-amino-1-methylquinolinium as a chemical compound, and the 2018 study that tested it describes it as a small molecule inhibitor of the enzyme NNMT.1,2
What it isA small quinolinium compound that inhibits the enzyme nicotinamide N-methyltransferase (NNMT), recorded by FDA’s substance registry as 5-amino-1-methylquinolinium.1,2
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3
Human evidenceNone found in the sources reviewed here: the 2018 study that introduced it tested cells and mice.2
Evidence strengthAnimal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned

What is 5-Amino-1MQ?

5-Amino-1MQ is a synthetic chemical compound, not a peptide. FDA’s substance registry records it as 5-amino-1-methylquinolinium, a charged quinolinium ion.1

It is one of a series of methylquinolinium compounds that researchers described in 2018 as small molecule inhibitors of nicotinamide N-methyltransferase (NNMT).2

How is 5-Amino-1MQ thought to work?

NNMT is an enzyme in fat cells and other tissues that plays a part in cellular energy use. In fat cells grown in the laboratory, NNMT inhibitors raised levels of NAD+ and S-adenosylmethionine and reduced fat formation, according to the 2018 study.2

The study reported that the compounds did not block several related enzymes it tested.2

What do human studies show?

None of the sources reviewed here describes a study of 5-Amino-1MQ in people.1,2

In the 2018 study, mice made obese by a high-fat diet lost weight over 11 days of treatment and had less white fat and lower cholesterol, while untreated mice gained slightly. The treated mice did not eat less.2

What the evidence base contains

  • Animal or laboratory research Cell studies of NNMT inhibitors, and an 11-day study in which mice made obese by a high-fat diet lost weight and white fat when given 5-amino-1MQ, without eating less.2

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is 5-Amino-1MQ FDA-approved?

None of the sources reviewed here reports an approval of 5-Amino-1MQ by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list 5-Amino-1MQ.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. 5-Amino-1MQ is not among them.4,5

Timeline

  1. Researchers report that 5-amino-1MQ and related NNMT inhibitors reversed diet-induced obesity in mice over 11 days.2
  2. FDA’s compounding safety-risk page is last updated; it does not list 5-Amino-1MQ.3

What is still unknown?

Whether it has any effect in people, and whether it is safe for people: the sources reviewed here report only cell and mouse research.2

Whether the short-term weight loss seen in mice lasts, since the study treated them for 11 days.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for 5-Amino-1MQ: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for 5-Amino-1MQ are a bounded selection, not every registration or paper about 5-Amino-1MQ. For the years before 5-Amino-1MQ was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list 5-Amino-1MQ as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name 5-Amino-1MQ in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

Status summary unavailable

This profile has no living status brief. Inspect the cited profile records below.

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to 5-Amino-1MQ?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

0Selected dated records
5Connected citations
0Populated source yearsNo dated records
0/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
0

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection

Research hub

Explore the 5-Amino-1MQ evidence record

No dated evidence record is published for this profile yet. The cited profile sources remain available below.
Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile

Updates connected to this profile

No dated evidence record is published for this profile. PeptideScanner does not monitor every source continuously; the current profile summary and cited records remain available.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    5-Amino-1-methylquinolinium substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice (2018) · PMID 29155147 ↗

    Biochemical Pharmacology · Official source · Source checked November 16, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026